Wednesday, March 6, 2013


Mavrilimumab is a human MAB for the treatment of rheumatoid arthritis. It targets the GMCSF receptor and alpha-chain. More at:

I have already talked about Mavrilimumab:

Now let's see how the story unfolds.
At the EULAR 2012 there had been three studies, but it didn't seem to be the start of a success story.

At the 2012 ACR Meeting in Washington there had been nothing. No abstract or poster appeared on mavrilimumab.

Early in 2013 I received a study on mavrilimumab. Here's the link: That hasn't been much more than the results published at the EULAR 2012. I was getting concerned about the missing progress in proving the drug's capabilities.

Just now I see a study recruting patients: "A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis" with no investigator namned. Primary Outcome Measures: Change from baseline in disease activity score
DAS28(CRP) and proportion of subjects showing an improvement (ACR critieria). Whole information is here: Estimated end of study April 2014.

Maybe the drug needs more time, but it's already been a long while since no really new information had been published.

New blogpost with data from EULAR 2013:

如有关于 Mavrilimumab 中国越来越感兴趣,提供中文译本。

No comments:

Post a Comment